Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC (4503)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on ASTELLAS PHARMA INC
02/23ASTELLAS PHARMA : Patent Application Titled "Pharmaceutical Composition Containi..
AQ
02/21ASTELLAS PHARMA : adding `off-the-shelf` stem cell tech in $102.5m acquisition
AQ
02/20ASTELLAS PHARMA : Launches Global Campaign in Collaboration with CNN as Part of ..
AQ
02/16ASTELLAS PHARMA : scoops up Universal Cells for $102.5m
AQ
02/16ASTELLAS PHARMA : Launches Global Campaign in Collaboration with CNN as Part of ..
PU
02/15DISCOVERY COMMUNICATIONS : Astellas Partners with Discovery Communications for i..
AQ
02/14ASTELLAS PHARMA : Acquires Universal Cells, Inc. (pdf 178KB)
PU
02/14ASTELLAS PHARMA : Partners with Discovery Communications for its Global Branding..
PU
02/13CENTRAL NERVOUS SYSTEM DRUGS MARKET : Central Nervous System Drugs Market Overv..
AQ
02/12ASTELLAS PHARMA : Announce Top-Line Results for Two Phase 3 Trials of Peficitini..
AQ
02/09BIOCENTURY - MANAGEMENT TRACKS : Arcturus, Kymera
AQ
02/08ASTELLAS PHARMA : Findings on Pain Reported by Investigators at Astellas Pharma ..
AQ
02/08ASTELLAS PHARMA : to Present New Oncology Data at the 2018 ASCO Genitourinary Ca..
AQ
02/08ASTELLAS PHARMA : Announce Top-Line Results for Two Phase 3 Trials of Peficitini..
PU
02/07ASTELLAS PHARMA : Phase 3 PROSPER trial shows Xtandi reduces risk of metastasis ..
AQ
02/06ASTELLAS PHARMA : CMV DNA Vaccine Candidate Fails to Meet Endpoints in Phase 3 T..
AQ
02/06PFIZER : Phase 3 PROSPER Trial Shows XTANDI (enzalutamide) Significantly Reduced..
AQ
02/05ASTELLAS PHARMA : Announces Acquisition of Own Shares
AQ
02/05ASTELLAS PHARMA : Announces Transition to a Company with an Audit & Supervisory ..
AQ
02/05ASTELLAS PHARMA : Announces Changes in Management Structure, Global Function, an..
PU
02/05ASTELLAS PHARMA : Announces Personnel Changes and Organizational Changes (pdf 30..
PU
02/02ASTELLAS PHARMA : Reports Financial Results for the First Nine Months of FY2017
AQ
02/01ASTELLAS PHARMA : and Vical Announce Top-Line Results for Phase 3 Trial of Cytom..
AQ
01/31ASTELLAS PHARMA : Announces Transition to a Company with an Audit & Supervisory ..
PU
01/31ASTELLAS PHARMA : Announces Acquisition of Own Shares (pdf 119KB)
PU
01/31ASTELLAS PHARMA : Reports Financial Results for the First Nine Months of FY2017 ..
PU
01/31ASTELLAS PHARMA : Reports Financial Results for the First Nine Months of FY2017
BU
01/30ASTELLAS PHARMA : to Present New Oncology Data at the 2018 ASCO Genitourinary Ca..
AQ
01/25ASTELLAS PHARMA : Receives Orphan Designation from the European Commission for G..
AQ
01/24Consortium unveils report to increase antibiotic innovation
AQ
01/24ASTELLAS PHARMA : Completes Acquisition of Mitobridge, Inc. (pdf 242KB)
PU
01/23GILEADS KITE TO BUY EX-AGENSYS R&D S : report
AQ
01/23ASTELLAS PHARMA : Receives Orphan Designation from the European Commission for G..
PU
01/22ASTELLAS PHARMA : and Vical Announce Top-Line Results for Phase 3 Trial of Cytom..
PU
01/19ASTELLAS PHARMA : Research Data from Astellas Pharma Update Understanding of Med..
AQ
01/19ASTELLAS PHARMA : Reports Summarize Central Nervous System Agents Findings from ..
AQ
01/19ASTELLAS PHARMA : New Pelvic Pain Study Findings Have Been Reported by Investiga..
AQ
01/15AMGEN : Astellas Pharma Inc - Repatha SC Injection 420 mg Auto Mini Doser Launch..
AQ
01/12ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
AQ
01/12ASTELLAS PHARMA : Repatha® SC Injection 420 mg Auto Mini Doser Launched in Japan..
PU
01/11ASTELLAS PHARMA : Researchers from Astellas Pharma Report New Studies and Findin..
AQ
01/11AMGEN : Astellas BioPharma K.K. - Application for Marketing Approval Submitted f..
AQ
01/11ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
PU
01/09ASTELLAS PHARMA : Application for Marketing Approval Submitted for Bispecific CD..
PU
01/06ASTELLAS PHARMA : Potenza Therapeutics Unveils Pipeline of Immuno-Oncology Progr..
AQ
01/04ASTELLAS PHARMA : New Tissue Engineering Data Have Been Reported by Researchers ..
AQ
01/04ASTELLAS PHARMA : Patent Application Titled "Pharmaceutical Composition Comprisi..
AQ
01/04ASTELLAS PHARMA : Reports on Pharmacokinetics Findings from Astellas Pharma Glob..
AQ
2017ASTELLAS PHARMA : ClearPath Development Company Launches Third Collaboration Und..
AQ
2017ASTELLAS PHARMA : to Present at J.P. Morgan Healthcare Conference
AQ
2017BIOCENTURY - MANAGEMENT TRACKS : CRISPR, Hua
AQ
2017Researchers develop hESC-derived RPE cell sheet
AQ
2017ASTELLAS PHARMA : to Present at J.P. Morgan Healthcare Conference (pdf 178KB)
PU
2017ASTELLAS PHARMA : New Findings from Astellas Pharma Global Development Inc. Upda..
AQ
2017ASTELLAS PHARMA : Announces First Clinical Data from Phase I Study of Gilteritin..
AQ
2017ASTELLAS PHARMA : Announces First Clinical Data from Phase I Study of Gilteritin..
PU
2017ASTELLAS PHARMA : the Institute of Medical Science of the University of Tokyo, C..
AQ
2017ASTELLAS PHARMA : New Prostate Cancer Study Results from Astellas Pharma Describ..
AQ
2017ASTELLAS PHARMA : to Present New Data Exploring Gilteritinib in Newly Diagnosed ..
AQ
2017ASTELLAS PHARMA : takes up option to buy US mitochondrial drug discovery partner
AQ
2017ASTELLAS PHARMA : the Institute of Medical Science of the University of Tokyo, C..
PU
2017ASTELLAS PHARMA : Announces Personnel Change
AQ
2017ASTELLAS PHARMA : Acquires Mitobridge Under Existing Collaboration
AQ
2017ASTELLAS PHARMA : BioCentury - Astellas acquires build-to-buy Mitobridge
AQ
2017ASTELLAS PHARMA : Submits a New Drug Application for Gonax 12-Week Extended-Rele..
AQ
2017ASTELLAS PHARMA : Announces Personnel Change(pdf 155KB)
PU
2017ASTELLAS PHARMA : Acquires Mitobridge Under Existing Collaboration(pdf 359KB)
PU
2017ASTELLAS PHARMA : Submits a New Drug Application for Gonax® 12-Week Extended-Rel..
PU
2017ASTELLAS PHARMA : to Present New Data Exploring Gilteritinib in Newly Diagnosed ..
AQ
2017ASTELLAS PHARMA : to Present New Data Exploring Gilteritinib in Newly Diagnosed ..
PU
2017ASTELLAS PHARMA : MSD and Astellas conclude co-promotion agreement in Japan for ..
PU
2017ASTELLAS PHARMA : Oncology Awards $100,000 in C3 Prize Grants to Five Innovators..
AQ
2017ASTELLAS PHARMA : Reports from Astellas Pharma Provide New Insights into Rheumat..
AQ
2017ASTELLAS PHARMA : Findings from Astellas Pharma Yields New Findings on Medicinal..
AQ
2017SEATTLE GENETICS : and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in..
AQ
1  2  3  4  5  6  7  8Next
Financials ( JPY)
Sales 2018 1 295 B
EBIT 2018 220 B
Net income 2018 180 B
Finance 2018 359 B
Yield 2018 2,39%
P/E ratio 2018 16,56
P/E ratio 2019 15,68
EV / Sales 2018 2,13x
EV / Sales 2019 2,07x
Capitalization 3 122 B
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 548  JPY
Spread / Average Target 2,6%
EPS Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Chikashi Takeda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
Hironobu Yasuda Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC5.38%29 217
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%222 939
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 036
MERCK AND COMPANY-3.02%148 618